This study was performed in order to evaluate the toxicities, progression-free and overall survival of patients with responsive residual or recurrent ovarian cancer treated with high-dose chemotherapy. Twenty-seven patients were treated. Doxorubicin, 165 mg/m 2 over 96 h (days −12 to −8), etoposide 700 mg/m 2 every day ×3 (days −6 to −4), and cyclophosphamide 4.2 g/m 2 on d −3 was followed by stem cells and granulocyte colonystimulating factor. The median days of granulocyte count Ͻ500/l was 14 (range 10-42) and platelets Ͻ20 000/l was 13 (range 2-80). Median numbers of red cell and platelet transfusions were 15 (5-16) and 14 (4-103). Toxicity included mucositis requiring narcotic analgesia in all patients. Asymptomatic decreases in ejection fraction to values Ͻ50% were observed in four patients. No clinical congestive heart failure was observed. One death due to sepsis was observed. Median progression-free survival is 7.5 months (1.0-56 months); five patients remain alive, two of whom remain progression-free at 19.5 and 24.5 months post transplant. Median overall survival is 14.0 months (1-68 months). We conclude that high-dose anthracyclines may be safely administered to ovarian cancer patients. The short overall and progression-free survivals observed in our population suggest that this combination is not optimal. Bone Marrow Transplantation ( when patients are treated with aggressive debulking surgery followed by platinum-based chemotherapy.
when patients are treated with aggressive debulking surgery followed by platinum-based chemotherapy. [1] [2] [3] At present, however, there is no proven curative therapy for patients having persistent disease following initial therapy, or for those whose disease recurs.
Steep dose-response relationships for anthracyclines and alkylating agents have been described for ovarian cancer. 4 Efforts to increase dose intensity and decrease toxicity include the use of bone marrow and/or peripheral blood stem cells for hematopoietic support. 5 The use of this approach in patients with residual or recurrent disease has resulted in long-term disease-free survivals of 15-25% in multiple phase II trials of high-dose chemotherapy, with plateaus in survival curves appearing at approximately the 3-year post-treatment time point. 6, 7 Multiple combinations of chemotherapeutic agents have been utilized as preparative regimens including platinum and non-platinum-based designs. Dottino et al 8 examined the effectiveness of etoposide in combination with cisplatin in previously treated patients and described a threshhold dose for etoposide, suggesting a dose-response relationship. Mulder et al 6 reported complete responses in six of eight patients with microscopic or Ͻ2 cm residual disease in patients treated with a combination of a dose-intense etoposide/cyclophosphamide combination. Jacobs et al 9 have analyzed the effect of dose intensity on survival in previously untreated ovarian cancer patients. Those who received high-dose intensities of cisplatin, doxorubicin, or all drugs combined survived significantly longer than those who received lower dose intensities. Based on these and other published series we were encouraged to undertake a phase II trial of intravenous doxorubicin, etoposide and cyclophosphamide utilizing stem cell support in patients with clinically persistent or recurrent responsive ovarian carcinoma. The chemotherapy doses were chosen based on phase I experience at our institution which documented that high-dose doxorubicin can be safely administered without significant cardiac toxicity when administered as a 96 h continuous infusion. 10 We report the results of that trial.
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Patients and methods
Patient selection
Between April 1992 and August 1998, 27 patients with persistent or responding recurrent, biopsy-proven coelomic epithelial cancers (epithelial ovarian, Fallopian tube or primary peritoneal carcinoma, all of which display similar clinical characteristics and have similar recommendations for management) were eligible for this trial. Newly diagnosed patients must have been previously treated with debulking surgery followed by platinum-based chemotherapy, and have sustained at least a partial response; those with recurrent ovarian cancer must have sustained at least a partial response following second-line chemotherapy documented by second-look surgery or radiographic or clinical evaluation. Patients were required to have a Karnofsky performance status of 80%, and physiologic age р55 years. Cardiac ejection fraction must have been Ͼ50% as measured by MUGA radionuclide scan. Adequate renal, hematopoietic, and hepatic function was defined as: serum creatinine р1.5 mg/dl or 24 h creatinine clearance of 50 ml/min; total white blood cell count 4000/l, platelet count 150 000/l, hemoglobin Ͼ10 g/dl; SGOT and SGPT within two times normal limits and serum bilirubin р1.5 mg/dl. All patients gave their voluntary informed consent and signed a consent document that had been reviewed and approved by the Institutional Review Boards of the City of Hope National Medical Center and Samaritan Hospital.
Pre-treatment evaluation
All patients had a complete history and physical examination including documentation of weight, Karnofsky performance status, presence of measurable or evaluable disease, a complete blood count with differential, platelet count, 18-channel blood chemistry analysis, serum CA-125 level, serum magnesium level, chest X-ray, electrocardiogram, radionuclide MUGA scan, urinalysis, and computed tomographic scans of the chest, abdomen and pelvis. A complete blood count with differential, and platelet count, and electrolyte evaluation were repeated daily while receiving chemotherapy and while myelosuppressed. The CA-125 level and MUGA scans were repeated 30 to 45 days afterhospital discharge, and thereafter at least every 3 months (more often at the discretion of the referring physician).
Treatment plan
Stem cell harvest: The first eight patients received bone marrow mononuclear cells (mean 2.71 × 10 8 /kg) supplemented by three collections of peripheral blood stem cells (mean 5.3 × 10 8 /kg). Granulocyte colony-stimulating factor (G-CSF) 5 g/kg was administered intravenously daily for 5 days; bone marrow stem cells were then harvested from the posterior iliac crest using standard techniques. 10 All patients then continued G-CSF for successive days during peripheral stem cell apheresis. After favorable re-engraftment data for peripheral blood stem cells alone became available, the stem cell support regimen was amended, and the remaining 19 patients had reinfusions of peripheral blood mononuclear cells alone (mean number 10.4 × 10 8 /kg) for hematopoietic support, which were mobilized, harvested, and stored using previously published methods. 10 Chemotherapy administration: Doxorubicin 165 mg/m 2 was administered by continuous intravenous infusion over 96 h via a dual lumen central venous (Hickman) catheter during the first 4 days of therapy (day −12 to day −8). On days −6 to −4, etoposide, 700 mg/m 2 /day was infused over 2 h. On day −3, cyclophosphamide 4.2 g/m 2 was administered over 2 h using MESNA as a uroprotectant. At least 2 × 10 8 mononuclear cells/kg (including both bone marrow and peripheral blood mononuclear cells) were rapidly thawed and reinfused on day 0 by rapid intravenous infusion. G-CSF 5 g/kg was administered intravenously daily starting on day 0 until the total white count was Ͼ1000/l for 3 consecutive days.
Statistical methods
Toxicities have been categorized using the Common Toxicity Criteria for Autologous Bone Marrow Transplantation of the National Cancer Institute. Overall and progressionfree survivals were calculated according to the method of Kaplan and Meier. 
Results
Patient characteristics
Twenty-seven patients were enrolled on this study, of whom 26 received the entire planned course of treatment. The patient characteristics are summarized in Tables 1 and  2 . All patients were eligible and evaluable for toxicity and are reported for progression-free and overall survival. The median age was 48 years (range 28-63), and the median Karnofsky performance status was 90% (range 80-100%). Twenty-two patients were Caucasian and five were Hispanic. Twenty-five of the patients were platinum-sensitive, while two progressed within 6 months of a platinum-containing regimen and were resistant. Disease status at entry on this study included: 15 patients with residual disease following debulking surgery and platinum-based chemotherapy; 13 of whom had stage 3 and two had stage 4 disease at the time of their initial diagnosis. Twelve patients had a recurrence of ovarian cancer that was responding to second-line chemotherapy. All of these patients had pretreatment CT scans and were judged to have recurrent disease of Ͻ1 cm. Nineteen patients had serous papillary adenocarcinomas, four had undifferentiated adenocarcinomas, one had clear cell carcinoma, two had endometrioid carcinomas, and one had a mucinous adenocarcinoma. All patients had undergone prior surgery and platinum-based chemotherapy; no patient had received prior radiation therapy.
Of the patients with residual disease following initial platinum-based chemotherapy, 12 were documented by a second-look surgical procedure and three by clinical status. Nine had only microscopic residual disease and six had Ͻ1 cm residual disease at this time. The median initial progression-free survival of those relapsed patients who responded to reinduction chemotherapy was 12 months (range 3-42). In the recurrent group the median number of chemotherapy courses administered prior to high-dose chemotherapy was two (range 1-4).
Progression-free and overall survival data
Progression-free and overall survival curves are shown in Figures 1 and 2 . The median progression-free and overall survivals are 7.5 months (range 1.0-56 months) and 14.0 months (range 1-68 months), respectively (8.3 and 14 months for patients with residual disease and 8 and 21 months for patients with recurrent disease (P values, log rank statistic, Ͼ0.44 for progression-free survival and Ͼ0.3 for overall survival)).
Four of 27 patients remain alive, one of whom remains clinically relapse-free at 42 months post transplant. One patient died of complications related to sepsis due to Enterobacter cloacae while on treatment, which developed on day +4. One patient who entered the trial with well-controlled asthma did not complete the planned course of chemotherapy due to the development of bronchospasm following the doxorubicin infusion and one of the three Bone Marrow Transplantation planned doses of etoposide, at which time the chemotherapy was stopped. She subsequently received her stem cell reinfusion and recovered without sequelae. Her CA-125 level rose 18 months following treatment; however, the patient remains alive and without clinical symptoms of disease 24.5 months following treatment.
Disease progression was documented by radiographic criteria in 18 patients, and clinically with accompanying increase or a new elevation of CA-125 levels in seven patients. One patient died while on treatment, and one patient remains without evidence of disease progression.
Pre-and post-treatment CA-125 levels and therapeutic outcomes
All patients were judged to be in response to induction or reinduction chemotherapy at the time that they were entered on this protocol and began stem cell collection. CA-125 levels (summarized in Table 3 ) were examined on day 1 of treatment and repeated at 30-45 days post transplant. Of the 27 patients who entered the trial, 22 had CA-125 levels within the normal limit (Ͻ35) on day 1 of chemotherapy. Of these, 16 remained within normal limits following the completion of treatment. Two patients who had CA-125 levels Ͻ20 pre-treatment increased to 49 and 459 post treatment. Of the four remaining patients (out of 22) beginning Table 3 CA-125 (units/ml, N1 р35 units/ml) levels pre-and post treatment therapy with levels 21-35, one patient died, one remained normal, and two increased to 50. Of the five patients who were found to have levels Ͼ35 on day 1 of chemotherapy, two decreased to the normal range, while three remained elevated following treatment (one stable (67 → 68), and two showing marked progression (310 → 2354 and 79 → 187)].
Hematologic recovery and toxicities of therapy
Hematologic recovery is summarized in Table 4 . The median number of days of thrombocytopenia (platelets Ͻ20 000/l) was 13 (mean 19, range 2-80). Neutropenia (500 neutrophils/l) persisted for a median of 14 days (mean 16, range 10-42 days). The median number of red cell and platelet transfusions administered were 15 and 14, respectively, with means of 8 and 17. Cardiac toxicity was mild. All patients except the patient who expired had follow-up MUGA scans within 1 to 3 months post treatment. Four patients had asymptomatic decreases in the ejection fraction from 57% (two patients) → 49% and 48%, and 59% (2 patients) → 48% and 45%. There was no observed clinical congestive heart failure. Grade 4 mucositis was universal with all patients requiring intravenous narcotic analgesics for pain control. All patients developed neutropenic fever requiring intravenous antibiotics. One patient developed systemic candidiasis at the time of engraftment requiring prolonged treatment with amphotericin B. One patient died following chemotherapy from complications of sepsis due to Enterobacter cloacae.
Discussion
Epithelial ovarian cancer is the leading cause of death from gynecologic malignancy and the fifth most common neoplasm in women in the United States. 12, 13 At the time of diagnosis, the majority of patients will have advanced disease; optimal initial treatment consists of debulking surgery followed by chemotherapy administration and results in approximately 15-25% long-term disease-free survival.
14 Table 4 Number of days required for hematologic recovery The role of anthracyclines in the chemotherapeutic management of advanced ovarian cancer has been evolving over the past 20 years. Sequential clinical trials of singleagent and combination chemotherapy that included doxorubicin initially suggested that anthracyclines improved overall and progression-free survival; however, subsequent phase III studies failed to confirm these findings. 15, 16 Thus, the current standard post-operative chemotherapy is six cycles of a platinum analogue with paclitaxel. This results in median progression-free and overall survival rates of approximately 18 and 38 months, respectively, in stage 3 and 4 patients. [17] [18] [19] A more recently published meta-analysis, 20 however, has reintroduced the question of the role of anthracyclines in the treatment of epithelial ovarian carcinoma, and suggests that these agents may increase overall and progression-free survival.
Despite the fact that first-line treatment of advanced ovarian cancer results in a 60-80% response rate with intravenous chemotherapy, the majority of these patients die of chemotherapy-resistant, recurrent disease. 21, 22 Patients with recurrent or residual disease following initial therapy have median progression-free and overall survival rates of 3.6 and 9.5 months, which have improved only 0.2 months/year from 1980 to 1997. 23 At present, there is no proven salvage treatment that results in long-term disease-free survivals in patients having residual disease following initial treatment, or in those patients with relapsed disease, irrespective of their response to second-line therapy. Because of these poor results, the role of dose intensification utilizing bone marrow stem cells for hematopoietic support has been investigated based on studies suggesting steep dose-response relationships in ovarian cancer patients. 9, 24 Retrospective and prospective non-randomized clinical trials of high-dose chemotherapy in epithelial ovarian cancer have confirmed high response rates and pathologic complete responses in chemotherapy-resistant patients. Furthermore, early reports of survival curves suggesting a plateau in progression-free and overall-survival at 24-48 months following treatment 6, 7 have been confirmed in more recent publications of Stiff et al, 25 Legros et al 26 and Shinozuka et al 27 Prognostic factors have been examined by Stiff et al. 25 They have shown that age, tumor bulk at the time of transplant, and platinum sensitivity, are predictive of longerterm survivals. Recent data from the European Intergroup (GINECO) study suggests a statistically significant median disease-free survival for patients receiving consolidation high-dose chemotherapy compared to patients receiving conventional-dose chemotherapy. 28 An analysis of predictive factors included a low tumor burden at the time of second-look surgery and the presence of paclitaxel in the initial chemotherapy regimen. The results of this multivari-ate analysis suggest that our patients should have been in a favorable group, however, the median progression-free and overall survivals are inferior to those in these reports and by Legros et al. 26 The reasons for this discrepancy are not readily apparent. The preparative regimens used by the cited authors utilized platinum, or melphalan-based regimens. It is possible that platinum, melphalan, or taxanebased regimens are more active and thus preferable for superior long-term results in ovarian cancer patients.
Our study has shown that dose-intense doxorubicin can be safely administered to patients with ovarian cancer in a high-dose combination regimen that includes etoposide and cyclophosphamide. However, the short overall and progression-free survivals observed in our study population suggest that this non-platinum containing combination is not optimal.
